RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.

BMC Cancer · 2020 · PMC7493344 · PMID 32933498

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

borderline significantp = 0.11not close (p > 0.1)

In colon cancer, the benefits of neoadjuvant induction chemotherapy are also being explored and recent data from the large randomized controlled FOxTROT trial ( n = 1052) demonstrated a 50% reduction in incomplete resection rates and a borderline significant improvement of the 2-year-failure rate (HR = 0.77, p = 0.11) for those patients receiving neoadjuvant induction therapy before undergoing surgical resection [ 19 ].

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.